<DOC>
	<DOCNO>NCT00247507</DOCNO>
	<brief_summary>The aim study explore identify effect acetylcysteine , common mucolytic anti-oxidant property , alleviate damage cause increased oxidative stress hemodialysis patient .</brief_summary>
	<brief_title>The Effects Acetylcysteine Alleviating Damage Oxidative Stress Hemodialysis Patients</brief_title>
	<detailed_description>Oxidative stress patient renal failure higher healthy control . Once undergoing hemodialysis ( HD ) therapy , patient end-stage renal disease even oxidative stress . Reactive oxygen specie ( ROS ) denature vital molecule , lipid , protein , nucleic acid . Increased ROS produce oxidize low-density lipoprotein ( ox-LDL ) , , turn , induce atherosclerosis subsequent cardiovascular disease . Cardiovascular disease lead cause death HD patient . On hand , ROS damage RBC membrane cause hemolysis . Hemolysis exaggerate uremic anemia result resistance erythropoietin ( EPO ) therapy . Acetylcysteine , common mucolytic , antioxidant well . In vivo experiment , acetylcysteine demonstrate inhibit production ox-LDL ROS . Acetylcysteine also show effective drug prevention contrast media-induced nephropathy high-risk patient . Thus hypothesize HD patient take acetylcysteine may less ox-LDL produce ROS , consequently , low risk cardiovascular disease . Moreover , less damage RBC membrane ROS , HD patient take acetylcysteine may milder anemia good responsiveness erythropoietin therapy . Therefore , plan conduct prospective trial , acetylcysteine administrate enrolled HD patient three month . The primary goal study realize change 1 ) plasma ox-LDL level , 2 ) anemia status , 3 ) responsiveness EPO therapy , 4 ) severity atherosclerosis . The secondary goal identify change oxidative stress pro-inflammatory status patient .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<criteria>On HD thrice week HD unit three month Informed consent The dose EPO iron supplement stationary previous one month No take acetylcysteine previous one month No use vitamin Ebonded dialysis membrane Severe liver disease ( AST ALT &gt; 40 IU/L ) , proven malignancy , severe cardiovascular disease ( proved cardiac catheter echography examination ) Active infection hospitalization previous one month Clinically significant bleeding episode previous one month Taking vitamin C , vitamin E know antioxidant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2005</verification_date>
	<keyword>Anemia</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>End-stage renal disease</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>Oxidative stress</keyword>
	<keyword>Pro-inflammation</keyword>
</DOC>